Bank Of America Corp Cassava Sciences Inc Call Options Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $725,406 - $2.66 Million	75,800 Added 256.95%	105,300 $3.1 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $185,250 - $391,650	15,000 Added 103.45%	29,500 $364,000
Q1 2024 May 15, 2024	BUY	$18.44 - $26.41 $267,380 - $382,945	14,500 New	14,500 $294,000
Q4 2022 Feb 10, 2023	SELL	$27.82 - $44.16 $1.23 Million - $1.95 Million	-44,100 Reduced 88.02%	6,000 $177,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $573,182 - $1.79 Million	35,100 Added 234.0%	50,100 $2.1 Million
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $1.77 Million - $3.95 Million	-102,800 Reduced 87.27%	15,000 $421,000
Q2 2021 Sep 13, 2021	BUY	$32.15 - $89.72 $3.79 Million - $10.6 Million	117,800 New	117,800 $10.1 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.